Fingolimod (FTY-720A, FTY720) Product Overview Product Name: Fingolimod (FTY-720A, FTY720) Alternate Name/Synonyms: FTY-720A, FTY720 Description: FTY720 can be phosphorylated by sphingosine kinase, which then acts as a potent agonist at four of the sphingosine-1-phosphate (S1P) receptors (S1P1, S1P3, S1P4, and S1P5). IC₅₀ of (S)- and (R)- FTY720-phosphate on lymphocyte migration toward 10 nM of S1P are 0.137 nM and 10.98 nM respectively. The IC₅₀ values to cell lines MCF-7 is 6.8±0.6 µM. Peptide Sequence: N/A Appearance: White solid Formulation: N/A CAS Number: 162359-56-0 Molecular Formula: C₁₉H₃₃NO₂.HCl Molecular Weight: 343.93 Purity: ≥98% by HPLC Solubility:DMSO (100 mg/ml) of EtOH (100 mg/ml) Storage Temp.: -20°C Shipping Conditions: RT Handling: Protect from air and moisture SMILES: CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl InChi: InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H InChi Key: SWZTYAVBMYWFGS-UHFFFAOYSA-N PubChem CID: 107969 MDL Number: MFCD00939512 USAGE: For Research Use Only! Not For Use in Humans.
Fingolimod (FTY-720A, FTY720) Product Overview Product Name: Fingolimod (FTY-720A, FTY720) Alternate Name/Synonyms: FTY-720A, FTY720 Description: FTY720 can be phosphorylated by sphingosine kinase, which then acts as a potent agonist at four of the sphingosine-1-phosphate (S1P) receptors (S1P1, S1P3, S1P4, and S1P5). IC₅₀ of (S)- and (R)- FTY720-phosphate on lymphocyte migration toward 10 nM of S1P are 0.137 nM and 10.98 nM respectively. The IC₅₀ values to cell lines MCF-7 is 6.8±0.6 µM. Peptide Sequence: N/A Appearance: White solid Formulation: N/A CAS Number: 162359-56-0 Molecular Formula: C₁₉H₃₃NO₂.HCl Molecular Weight: 343.93 Purity: ≥98% by HPLC Solubility:DMSO (100 mg/ml) of EtOH (100 mg/ml) Storage Temp.: -20°C Shipping Conditions: RT Handling: Protect from air and moisture SMILES: CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl InChi: InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H InChi Key: SWZTYAVBMYWFGS-UHFFFAOYSA-N PubChem CID: 107969 MDL Number: MFCD00939512 USAGE: For Research Use Only! Not For Use in Humans.
货号: F-4633-1 g 产品名称: Fingolimod, Hydrochloride Salt 品牌: LC 规格: 1 g
F-4633 Fingolimod, Hydrochloride Salt, >99%[FTY-720A] [FTY720] Related Terms: [Gilenia] [Gilenya]M.W. 343.93 C19H33NO2•HCl [162359-56-0] M.I. 14: 4083 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concentration of 200 µM. In contrast, even a 1-to-1,000 dilution of the same 13.8 mg/mL DMSO stock solution into a 10 mM phosphate-buffered saline at pH 7 results in a precipitate. Thus, fingolimod-HCl solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Either DMSO, ethanol or plain water should be used as the solvent until the final dilution is made into culture medium. Buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. “Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.” Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. “Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.” Pharmacol. Ther. 117: 77-93 (2008). •Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. “FTY720—the first compound of a new promising class of immunosuppressive drugs.” Nephrol. Dial. Transplant. 19: 1677-1681 (2004). •Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. “Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.” Clin. Transplant. 20: 788-795 (2006). •Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and
F-4633 Fingolimod, Hydrochloride Salt, >99%[FTY-720A] [FTY720] Related Terms: [Gilenia] [Gilenya]M.W. 343.93 C19H33NO2•HCl [162359-56-0] M.I. 14: 4083 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concentration of 200 µM. In contrast, even a 1-to-1,000 dilution of the same 13.8 mg/mL DMSO stock solution into a 10 mM phosphate-buffered saline at pH 7 results in a precipitate. Thus, fingolimod-HCl solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Either DMSO, ethanol or plain water should be used as the solvent until the final dilution is made into culture medium. Buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. “Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.” Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. “Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.” Pharmacol. Ther. 117: 77-93 (2008). •Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. “FTY720—the first compound of a new promising class of immunosuppressive drugs.” Nephrol. Dial. Transplant. 19: 1677-1681 (2004). •Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. “Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.” Clin. Transplant. 20: 788-795 (2006). •Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and
货号: F-4633-2 g 产品名称: Fingolimod, Hydrochloride Salt 品牌: LC 规格: 2 g
F-4633 Fingolimod, Hydrochloride Salt, >99%[FTY-720A] [FTY720] Related Terms: [Gilenia] [Gilenya]M.W. 343.93 C19H33NO2•HCl [162359-56-0] M.I. 14: 4083 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concentration of 200 µM. In contrast, even a 1-to-1,000 dilution of the same 13.8 mg/mL DMSO stock solution into a 10 mM phosphate-buffered saline at pH 7 results in a precipitate. Thus, fingolimod-HCl solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Either DMSO, ethanol or plain water should be used as the solvent until the final dilution is made into culture medium. Buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. “Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.” Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. “Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.” Pharmacol. Ther. 117: 77-93 (2008). •Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. “FTY720—the first compound of a new promising class of immunosuppressive drugs.” Nephrol. Dial. Transplant. 19: 1677-1681 (2004). •Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. “Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.” Clin. Transplant. 20: 788-795 (2006). •Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and
F-4633 Fingolimod, Hydrochloride Salt, >99%[FTY-720A] [FTY720] Related Terms: [Gilenia] [Gilenya]M.W. 343.93 C19H33NO2•HCl [162359-56-0] M.I. 14: 4083 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concentration of 200 µM. In contrast, even a 1-to-1,000 dilution of the same 13.8 mg/mL DMSO stock solution into a 10 mM phosphate-buffered saline at pH 7 results in a precipitate. Thus, fingolimod-HCl solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Either DMSO, ethanol or plain water should be used as the solvent until the final dilution is made into culture medium. Buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. “Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.” Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. “Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.” Pharmacol. Ther. 117: 77-93 (2008). •Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. “FTY720—the first compound of a new promising class of immunosuppressive drugs.” Nephrol. Dial. Transplant. 19: 1677-1681 (2004). •Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. “Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.” Clin. Transplant. 20: 788-795 (2006). •Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and
F-4633 Fingolimod, Hydrochloride Salt, >99%[FTY-720A] [FTY720] Related Terms: [Gilenia] [Gilenya]M.W. 343.93 C19H33NO2•HCl [162359-56-0] M.I. 14: 4083 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concentration of 200 µM. In contrast, even a 1-to-1,000 dilution of the same 13.8 mg/mL DMSO stock solution into a 10 mM phosphate-buffered saline at pH 7 results in a precipitate. Thus, fingolimod-HCl solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Either DMSO, ethanol or plain water should be used as the solvent until the final dilution is made into culture medium. Buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. “Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.” Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. “Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.” Pharmacol. Ther. 117: 77-93 (2008). •Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. “FTY720—the first compound of a new promising class of immunosuppressive drugs.” Nephrol. Dial. Transplant. 19: 1677-1681 (2004). •Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. “Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.” Clin. Transplant. 20: 788-795 (2006). •Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and
货号: F-4633-5 g 产品名称: Fingolimod, Hydrochloride Salt 品牌: LC 规格: 5 g
F-4633 Fingolimod, Hydrochloride Salt, >99%[FTY-720A] [FTY720] Related Terms: [Gilenia] [Gilenya]M.W. 343.93 C19H33NO2•HCl [162359-56-0] M.I. 14: 4083 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concentration of 200 µM. In contrast, even a 1-to-1,000 dilution of the same 13.8 mg/mL DMSO stock solution into a 10 mM phosphate-buffered saline at pH 7 results in a precipitate. Thus, fingolimod-HCl solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Either DMSO, ethanol or plain water should be used as the solvent until the final dilution is made into culture medium. Buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. “Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.” Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. “Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.” Pharmacol. Ther. 117: 77-93 (2008). •Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. “FTY720—the first compound of a new promising class of immunosuppressive drugs.” Nephrol. Dial. Transplant. 19: 1677-1681 (2004). •Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. “Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.” Clin. Transplant. 20: 788-795 (2006). •Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and
F-4633 Fingolimod, Hydrochloride Salt, >99%[FTY-720A] [FTY720] Related Terms: [Gilenia] [Gilenya]M.W. 343.93 C19H33NO2•HCl [162359-56-0] M.I. 14: 4083 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concentration of 200 µM. In contrast, even a 1-to-1,000 dilution of the same 13.8 mg/mL DMSO stock solution into a 10 mM phosphate-buffered saline at pH 7 results in a precipitate. Thus, fingolimod-HCl solubility in PBS is likely to be well below 100 µM, perhaps as low as 1-10 µg/mL. Either DMSO, ethanol or plain water should be used as the solvent until the final dilution is made into culture medium. Buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. “Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.” Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. “Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.” Pharmacol. Ther. 117: 77-93 (2008). •Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. “FTY720—the first compound of a new promising class of immunosuppressive drugs.” Nephrol. Dial. Transplant. 19: 1677-1681 (2004). •Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. “Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.” Clin. Transplant. 20: 788-795 (2006). •Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and
Fingolimod Hydrochloride Description Fingolimod Hydrochloride traps lymphocytes in lymph nodes, preventing them from moving to the central nervous system for auto-immune responses in multiple sclerosis. Specifications Cas No. 162359-56-0 Product ID F3454 Product Name Fingolimod Hydrochloride Formula Wt. 343.93 Store Temp Ambient References FTY720 (Fingolimod) for Relapsing Multiple Sclerosis, Expert Review of Neurotherapeutics, Alejandro Horga; Xavier Montalban 06/04/2008; Expert Rev Neurother. 2008;8(5):699-714
Fingolimod Hydrochloride Description Fingolimod Hydrochloride traps lymphocytes in lymph nodes, preventing them from moving to the central nervous system for auto-immune responses in multiple sclerosis. Specifications Cas No. 162359-56-0 Product ID F3454 Product Name Fingolimod Hydrochloride Formula Wt. 343.93 Store Temp Ambient References FTY720 (Fingolimod) for Relapsing Multiple Sclerosis, Expert Review of Neurotherapeutics, Alejandro Horga; Xavier Montalban 06/04/2008; Expert Rev Neurother. 2008;8(5):699-714
Fingolimod Hydrochloride Description Fingolimod Hydrochloride traps lymphocytes in lymph nodes, preventing them from moving to the central nervous system for auto-immune responses in multiple sclerosis. Specifications Cas No. 162359-56-0 Product ID F3454 Product Name Fingolimod Hydrochloride Formula Wt. 343.93 Store Temp Ambient References FTY720 (Fingolimod) for Relapsing Multiple Sclerosis, Expert Review of Neurotherapeutics, Alejandro Horga; Xavier Montalban 06/04/2008; Expert Rev Neurother. 2008;8(5):699-714